Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 30: | Line 30: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Eosinophils | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE | ||
|- | |- | ||
Line 38: | Line 38: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule | ||
|- | |- | ||
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders | ! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Atopic dermatitis | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Epidermal barrier dysfunction | * Epidermal barrier dysfunction | ||
* Immune dysregulation | * [[Immune]] dysregulation | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Incidence is highest during infancy and early childhood. | * [[Incidence]] is highest during [[infancy]] and early childhood. | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 54: | Line 53: | ||
* Infiltrated [[erythema]], [[prurigo]], scales and crusts | * Infiltrated [[erythema]], [[prurigo]], scales and crusts | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Young children -Scalp, cheeks amd extensor surface | * Young children -[[Scalp]], [[cheeks]] amd [[extensor]] surface | ||
* Adolescents -flexural areas and buttock-thigh creases | * [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases | ||
* Adults - facial involvement and skin flexures | * Adults - facial involvement and skin flexures | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
Line 70: | Line 69: | ||
* Infra-auricular and retro-auricular fissuring | * Infra-auricular and retro-auricular fissuring | ||
* Nipple eczema | * Nipple [[eczema]] | ||
* White dermographism | * White dermographism | ||
* Perifollicular accentuation | * Perifollicular accentuation | ||
| align="center" style="background:#F5F5F5;" | Nl to ↑ | | align="center" style="background:#F5F5F5;" | Nl to ↑ | ||
(Eosinophilia) | ([[Eosinophilia|Eosinophilia)]] | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 82: | Line 81: | ||
* [[Hyperkeratosis]] | * [[Hyperkeratosis]] | ||
* Psoriasiform hyperplasia | * Psoriasiform [[hyperplasia]] | ||
* Dyskeratosis | * Dyskeratosis | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
Line 92: | Line 91: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Delayed-type hypersensitivity response | * Delayed-type [[hypersensitivity]] response | ||
* Skin inflammation mediated by hapten-specific T cells | * Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Any | | align="center" style="background:#F5F5F5;" |Any | ||
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | | align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure | ||
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules | | align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]] | ||
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | | align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
Line 106: | Line 105: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Stinging and burning | * Stinging and burning | ||
* Localized swelling | * Localized [[swelling]] | ||
* Lichenified pruritic plaques | * [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]] | ||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | ([[Eosinophilia]]) | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Eosinophilic spongiosis and microvesicles | * [[Eosinophilic]] spongiosis and [[microvesicles]] | ||
* Exocytosis of eosinophils and lymphocytes | * [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]] | ||
* Chronic - Hyperkeratosis and parakeratosis | * Chronic - [[Hyperkeratosis]] and parakeratosis | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Contact with allergens in the past 1-2 days | * Contact with allergens in the past 1-2 days | ||
Line 121: | Line 120: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Activation of the innate immune system by the pro-inflammatory properties of chemicals | * Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Any, more occupational exposure | | align="center" style="background:#F5F5F5;" |Any, more with occupational exposure | ||
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | | align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure | ||
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | | align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface | ||
Line 133: | Line 132: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Swelling, blistering and scaling of the damaged area | * [[Swelling]], [[Blister|blistering]] and scaling of the damaged area | ||
* Dryness | * Dryness | ||
* Thicker skin | * Thicker skin | ||
Line 140: | Line 139: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Spongiosis | * Spongiosis | ||
* Intraepidermal vesicles or bullae | * Intraepidermal [[vesicles]] or bullae | ||
* Necrosis of keratinocytes | * [[Necrosis]] of [[keratinocytes]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Cumulative exposure to irritants | * Cumulative exposure to irritants | ||
Line 154: | Line 153: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Cradle cap - yellowish scales on the scalp | * [[Cradle cap]] - yellowish scales on the [[Scalp rash|scalp]] | ||
* Patchy or diffuse greasy scaling with or without a yellow-red base | * Patchy or diffuse greasy scaling with or without a yellow-red base | ||
* Crusts | * Crusts | ||
Line 164: | Line 163: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Infants: | * Infants: | ||
** | ** [[Cradle cap]] (Sclap) - non-inflammatory greasy scales on the scalp | ||
** Asymptomatic | ** Asymptomatic | ||
** Self resolving | ** Self resolving | ||
Line 171: | Line 170: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Focal parakeratosis and spongiosis in epidermis | * Focal parakeratosis and spongiosis in epidermis | ||
* Psoriasiform hyperplasia | * Psoriasiform [[hyperplasia]] | ||
* Neutrophils at the margins | * [[Neutrophils]] at the margins | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Stress | * Stress | ||
Line 182: | Line 181: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Keratinocyte hyperproliferation | * [[Keratinocyte]] hyperproliferation | ||
* Dysregulation of the immune system | * Dysregulation of the [[immune system]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years | | align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales | | align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Scalp | * Scalp | ||
Line 199: | Line 198: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Auspitz sign (pinpoint bleeding) | * [[Auspitz's sign]] (pinpoint bleeding) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Epidermal hyperplasia | * [[Epidermal]] [[hyperplasia]] | ||
* Parakeratosis | * Parakeratosis | ||
* Neutrophils microabscesses (Munro microabscesses) | * [[Neutrophils]] microabscesses (Munro microabscesses) | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Smoking | * Smoking | ||
Line 217: | Line 216: | ||
! align="center" style="background:#DCDCDC;" |[[Lichen simplex chronicus|Lichen simplex]] <ref name="pmid28785363">{{cite journal |vauthors=Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G |title=Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade |journal=Open Access Maced J Med Sci |volume=5 |issue=4 |pages=556–557 |date=July 2017 |pmid=28785363 |pmc=5535688 |doi=10.3889/oamjms.2017.133 |url=}}</ref>[[Lichen simplex chronicus|chronicus]] | ! align="center" style="background:#DCDCDC;" |[[Lichen simplex chronicus|Lichen simplex]] <ref name="pmid28785363">{{cite journal |vauthors=Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G |title=Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade |journal=Open Access Maced J Med Sci |volume=5 |issue=4 |pages=556–557 |date=July 2017 |pmid=28785363 |pmc=5535688 |doi=10.3889/oamjms.2017.133 |url=}}</ref>[[Lichen simplex chronicus|chronicus]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * Secondary to extensive [[pruritus]] due to other conditions such as [[Atopic dermatitis|atopic dermatitis,]] neuropathic pruritus, etc | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age | | align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | Lichenified and erythematous, pruritic exudative plaque, and excoriations | | align="center" style="background:#F5F5F5;" | [[Lichenification|Lichenified]] and [[erythematous]], [[Itch|pruritic]] [[exudative]] [[Plaques|plaque]], and excoriations | ||
| align="center" style="background:#F5F5F5;" | Scalp, head, neck, hands, arms, and genitals areas | | align="center" style="background:#F5F5F5;" | Scalp, head, neck, hands, arms, and genitals areas | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
Line 229: | Line 228: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Color of plaque varies | * Color of [[Plaques|plaque]] varies from yellow to reddish brown | ||
* Plaque size can vary between 3X6 cm 6X10 cm areas. | * [[Plaque]] size can vary between 3X6 cm 6X10 cm areas. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Markedly hyperplastic epidermis | * Markedly [[Hyperplasia|hyperplastic]] [[epidermis]] | ||
* Irregular hyperkeratosis and parakeratosis | * Irregular [[hyperkeratosis]] and parakeratosis | ||
* Thick granular zone | * Thick granular zone | ||
* Acanthosis | * [[Acanthosis]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Emotional stress | * Emotional stress | ||
Line 251: | Line 250: | ||
! align="center" style="background:#DCDCDC;" |[[Ichthyosis vulgaris]]<ref name="pmid23301728">{{cite journal |vauthors=Thyssen JP, Godoy-Gijon E, Elias PM |title=Ichthyosis vulgaris: the filaggrin mutation disease |journal=Br. J. Dermatol. |volume=168 |issue=6 |pages=1155–66 |date=June 2013 |pmid=23301728 |doi=10.1111/bjd.12219 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Ichthyosis vulgaris]]<ref name="pmid23301728">{{cite journal |vauthors=Thyssen JP, Godoy-Gijon E, Elias PM |title=Ichthyosis vulgaris: the filaggrin mutation disease |journal=Br. J. Dermatol. |volume=168 |issue=6 |pages=1155–66 |date=June 2013 |pmid=23301728 |doi=10.1111/bjd.12219 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Loss of function mutations in the filaggrin gene (''FLG'') | * Loss of function [[mutations]] in the [[Filaggrin|filaggrin gene (''FLG'')]] | ||
* Autosomal dominant inheritance with incomplete penetrance | * [[Autosomal dominant inheritance]] with [[incomplete penetrance]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 258: | Line 257: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Xerosis and gray scaling | * [[Xerosis]] and gray [[Ichthyosis|scaling]] | ||
* Palmar hyperlinearity | * [[Palmar]] hyperlinearity | ||
* Keratosis pilaris | * [[Keratosis pilaris]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Extensor surfaces of the extremities | * Extensor surfaces of the extremities | ||
Line 274: | Line 273: | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Reduced keratohyalin granules | * Reduced keratohyalin [[granules]] | ||
* Perinuclear keratin retractions in granular cells | * [[Perinuclear space|Perinuclear]] [[keratin]] retractions in [[Granule cell|granular]] cells | ||
* Thick stratum corneum | * Thick [[stratum corneum]] | ||
* Basket-weave pattern of stratum corneum | * Basket-weave pattern of [[stratum corneum]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Dry and cold weather | * Dry and cold weather | ||
Line 289: | Line 288: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Symmetrical coin-shaped erythematous plaques | * Symmetrical coin-shaped [[Erythematous rash|erythematous]] [[plaques]] | ||
* Erosions and excoriations | * Erosions and excoriations | ||
* Chronic lesions- central clearing leading to annular lesions | * Chronic lesions- central clearing leading to annular lesions | ||
Line 300: | Line 299: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Chronically lesions result into central clearing leading to annular lesions. | * Chronically [[lesions]] result into central clearing leading to annular lesions. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Spongiosis | * Spongiosis | ||
* Perivascular lymphocytic infiltrates, with eosinophils and occasional neutrophils | * [[Perivascular cell|Perivascular]] [[lymphocytic]] infiltrates, with [[eosinophils]] and occasional [[neutrophils]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Risk factors: | * Risk factors: | ||
Line 317: | Line 316: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Netherton's syndrome]]<ref name="pmid10835624">{{cite journal |vauthors=Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A |title=Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome |journal=Nat. Genet. |volume=25 |issue=2 |pages=141–2 |date=June 2000 |pmid=10835624 |doi=10.1038/75977 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Netherton's syndrome]]<ref name="pmid10835624">{{cite journal |vauthors=Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A |title=Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome |journal=Nat. Genet. |volume=25 |issue=2 |pages=141–2 |date=June 2000 |pmid=10835624 |doi=10.1038/75977 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (''SPINK5), encoding LEKTI'', a serine protease inhibitor | | align="center" style="background:#F5F5F5;" | [[Autosomal recessive]] [[mutations]] in the [[SPINK5|serine protease inhibitor of Kazal type 5 gene (''SPINK5)'']]'', encoding [[LEKTI]]''[[LEKTI|, a serine protease inhibitor]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Affects neonates | | align="center" style="background:#F5F5F5;" | Affects [[neonates]] | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 326: | Line 325: | ||
** Congenital ichthyosiform erythroderma | ** Congenital ichthyosiform erythroderma | ||
** Trichorrhexis invaginata | ** Trichorrhexis invaginata | ||
** Allergic diseases with ↑ serum IgE levels | ** [[Atopy|Allergic diseases]] with ↑ serum [[IgE]] levels | ||
* Ichthyosis linearis circumflexa (ILC) - serpiginous plaques with double scale at the margins | * Ichthyosis linearis circumflexa (ILC) - [[serpiginous]] [[plaques]] with double scale at the margins | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Diffuse pattern | * Diffuse pattern | ||
Line 350: | Line 349: | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * Psoriasiform [[hyperplasia]] | ||
* Reduced granular layer | * Reduced granular layer | ||
* Dyskeratosis | * Dyskeratosis | ||
* Dermal inflammatory infiltrate including neutrophils and eosinophils | * [[Dermal]] [[inflammatory]] infiltrate including [[neutrophils]] and [[eosinophils]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Atopic diseases including asthma, atopic dermatitis and allergic rhinitis | * Atopic diseases including asthma, atopic dermatitis and allergic rhinitis | ||
Line 381: | Line 380: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! align="center" style="background:#DCDCDC;" |[[Molluscum contagiosum]] | ! align="center" style="background:#DCDCDC;" |[[Molluscum contagiosum]] | ||
| align="center" style="background:#F5F5F5;" | Molluscum contagiosum virus inoculation through direct skin contact | | align="center" style="background:#F5F5F5;" | [[Molluscum contagiosum]] virus [[inoculation]] through direct skin contact | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 387: | Line 386: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Flesh-colored, dome-shaped papules with a central umbilication | * Flesh-colored, dome-shaped [[papules]] with a central umbilication | ||
* Lesions are 2-5mm in diameter | * Lesions are 2-5mm in diameter | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Face, trunk, antecubital, popliteal fossae and groin | * Face, trunk, [[Antecubital fossa|antecubital]], [[Popliteal fossa|popliteal fossae]] and groin | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | | align="center" style="background:#F5F5F5;" | If [[molluscum contagiosum]] is acquired as [[sexually transmitted disease]], it involves, groin and genital region. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Keratinocytes containing eosinophilic inclusion bodies (Henderson-Paterson bodies) | * [[Keratinocytes]] containing [[eosinophilic]] [[inclusion bodies]] (Henderson-Paterson bodies) | ||
* H&E stain - inwards indentation of the epidermis | * [[H&E stain]] - inwards indentation of the [[epidermis]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Often asymptomatic | * Often asymptomatic | ||
Line 410: | Line 409: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders | ||
! align="center" style="background:#DCDCDC;" |[[Dermatitis herpetiformis]]<ref name="pmid22137227">{{cite journal |vauthors=Kárpáti S |title=Dermatitis herpetiformis |journal=Clin. Dermatol. |volume=30 |issue=1 |pages=56–9 |date=2012 |pmid=22137227 |doi=10.1016/j.clindermatol.2011.03.010 |url=}}</ref> | ! align="center" style="background:#DCDCDC;" |[[Dermatitis herpetiformis]]<ref name="pmid22137227">{{cite journal |vauthors=Kárpáti S |title=Dermatitis herpetiformis |journal=Clin. Dermatol. |volume=30 |issue=1 |pages=56–9 |date=2012 |pmid=22137227 |doi=10.1016/j.clindermatol.2011.03.010 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | | align="center" style="background:#F5F5F5;" | [[Autoimmunity|Autoimmune]] disorder as a result of [[gluten sensitivity]] leading to the formation of [[IgA]] antibodies | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 416: | Line 415: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Excoriated papules | * Excoriated [[papules]], [[plaques]] and [[vesicles]] arranged in a clustered fashion | ||
* Symmetrical | * Symmetrical | ||
* Erosions and excoriations | * Erosions and excoriations | ||
Line 426: | Line 425: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Oral manifestation such as vesicles and erosion may be present | * Oral manifestation such as [[vesicles]] and erosion may be present | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Papillary micro-abscesses | * [[Papillary]] micro-[[abscesses]] | ||
* Sub-epidermal blisters containing neutrophils, eosinophils, and fibrin | * Sub-epidermal [[blisters]] containing [[neutrophils]], [[eosinophils]], and [[fibrin]] | ||
* Sub-epidermal vacuolization | * Sub-epidermal [[vacuolization]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Intermittent pruritic papules and vesicles | * Intermittent pruritic papules and vesicles | ||
Line 441: | Line 440: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid24817816">{{cite journal |vauthors=Buchbinder D, Nugent DJ, Fillipovich AH |title=Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments |journal=Appl Clin Genet |volume=7 |issue= |pages=55–66 |date=2014 |pmid=24817816 |pmc=4012343 |doi=10.2147/TACG.S58444 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid24817816">{{cite journal |vauthors=Buchbinder D, Nugent DJ, Fillipovich AH |title=Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments |journal=Appl Clin Genet |volume=7 |issue= |pages=55–66 |date=2014 |pmid=24817816 |pmc=4012343 |doi=10.2147/TACG.S58444 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Mutation in the gene encoding for Wiskott-Aldrich syndrome protein (WASp) on the short arm of the X chromosome | * Mutation in the gene encoding for [[Wiskott-Aldrich syndrome]] protein (WASp) on the short arm of the [[X chromosome]] | ||
* X-linked disorder | * [[X linked inheritance|X-linked disorder]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
Line 448: | Line 447: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Rash is clinically similar to atopic dermatitis | * Rash is clinically similar to [[atopic dermatitis]] | ||
* Erythematous and pruritic lesions | * [[Erythematous]] and [[Itch|pruritic]] lesions | ||
* Lesions can bleed due to thrombocytopenia | * Lesions can bleed due to [[thrombocytopenia]] | ||
* Cutaneous manifestations includes petechiae and ecchymosis | * Cutaneous manifestations includes [[Petechia|petechiae]] and [[ecchymosis]] | ||
| align="center" style="background:#F5F5F5;" | Rash can involve lesions located at the same areas of classical atopic dermatitis: | | align="center" style="background:#F5F5F5;" | Rash can involve lesions located at the same areas of classical atopic dermatitis: | ||
Line 459: | Line 458: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | | align="center" style="background:#F5F5F5;" | Infants can present with [[petechiae]], prolonged [[bleeding]] from [[umbilicus]] or circumcision, [[purpura]],[[hematemesis]], [[melena]], [[epistaxis]], [[hematuria]] or unusal bruising | ||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
Line 466: | Line 465: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Hyperkeratosis]] | * [[Hyperkeratosis]] | ||
* Psoriasiform hyperplasia | * Psoriasiform [[hyperplasia]] | ||
* Dyskeratosis | * Dyskeratosis | ||
Line 483: | Line 482: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyper-IgE syndrome]]<ref name="pmid24058807">{{cite journal |vauthors=Mogensen TH |title=STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties |journal=JAKSTAT |volume=2 |issue=2 |pages=e23435 |date=April 2013 |pmid=24058807 |pmc=3710320 |doi=10.4161/jkst.23435 |url=}}</ref> | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyper-IgE syndrome]]<ref name="pmid24058807">{{cite journal |vauthors=Mogensen TH |title=STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties |journal=JAKSTAT |volume=2 |issue=2 |pages=e23435 |date=April 2013 |pmid=24058807 |pmc=3710320 |doi=10.4161/jkst.23435 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Defects in the JAK-STAT signaling pathway leading to dysfunctional T helper cell type 17 (Th17) differentiation | * Defects in the [[JAK-STAT signaling pathway]] leading to dysfunctional [[T helper cell]] type 17 ([[T helper 17 cell|Th17]]) [[differentiation]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
Line 490: | Line 489: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Papulopustular | * Papulopustular | ||
* Severely pruritic eczematous rash | * Severely [[Itch|pruritic]] eczematous rash | ||
* Pustular and may impetiginized | * [[Pustular rash|Pustular]] and may impetiginized | ||
* Lichenification may occur | * [[Lichenification]] may occur | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Face and scalp | * Face and scalp | ||
Line 504: | Line 503: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Characteristic coarse facies | * Characteristic coarse facies | ||
* Increased alar width and broad nasal bridge | * Increased alar width and broad [[nasal bridge]] | ||
* High-arched oral palate | * High-arched oral palate | ||
* Hyperextensible joints | * Hyperextensible joints | ||
Line 512: | Line 511: | ||
| align="center" style="background:#F5F5F5;" | ↑ | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Eosinophil-rich infiltration around the hair follicles | * [[Eosinophil]]-rich infiltration around the hair follicles | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Cold abscesses | * Cold abscesses | ||
Line 525: | Line 524: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mycosis fungoides]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mycosis fungoides]] | ||
| align="center" style="background:#F5F5F5;" | Clonal expansion of CD4<sup>+</sup> memory T cells (CD45RO<sup>+</sup>) | | align="center" style="background:#F5F5F5;" | Clonal expansion of [[CD4+ cell|CD4]]<sup>+</sup> [[memory T cells]] (CD45RO<sup>+</sup>) | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 531: | Line 530: | ||
| align="center" style="background:#F5F5F5;" | Multiple | | align="center" style="background:#F5F5F5;" | Multiple | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Non pruritic patches and intensely pruritic plaques | * Non-pruritic patches and intensely [[Itch|pruritic]] [[plaques]] | ||
* Comedones, cysts | * [[Comedones]], [[cysts]] | ||
* Tumors of skin | * [[Tumors]] of skin | ||
* Erythematous macules | * [[Erythematous]] [[macules]] | ||
* Hypopigmented patches | * [[Hypopigmented area|Hypopigmented]] patches | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Asymmetrical | * Asymmetrical | ||
Line 544: | Line 543: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Alopecia | * [[Alopecia]] | ||
* Acneiform lesions | * [[Acneiform eruption|Acneiform]] lesions | ||
* Plaques size can vary between 2-20 cm | * [[Plaques]] size can vary between 2-20 cm | ||
* Lymphadenopathy | * [[Lymphadenopathy]] | ||
* Children- hypopigmented patches most common | * Children- [[Hypopigmentation|hypopigmented]] patches most common | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Perifollicular infiltrates around the infundibulum | * Perifollicular infiltrates around the [[infundibulum]] | ||
* Epidermis is spared or has minimal spongiosis | * [[Epidermis]] is spared or has minimal spongiosis | ||
* Band-like | * Band-like [[Dermal|derma]]<nowiki/>l infiltrate of [[lymphocytes]] and and [[histiocytes]] | ||
| colspan="2" align="center" style="background:#F5F5F5;" | | | colspan="2" align="center" style="background:#F5F5F5;" | | ||
* Increased risk of : | * Increased risk of : | ||
** Severe viral and bacterial infections | ** Severe viral and bacterial infections | ||
** Secondary malignancies, especially lymphomas | ** Secondary [[malignancies]], especially lymphomas | ||
* Staging of Mycosis fungoides is based upon: | * Staging of [[Mycosis fungoides]] is based upon: | ||
** Patches | ** Patches | ||
** Plaques | ** [[Plaques]] | ||
** Skin tumors | ** Skin tumors | ||
** Lymphadenopathy | ** [[Lymphadenopathy]] | ||
** Erythroderma | ** [[Erythroderma]] | ||
** Histology | ** [[Histology]] | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category |
Revision as of 16:42, 25 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Para-clinical findings | Associated factors | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | Symptoms | Physical examination | ||||||||||||||||
Lab Findings | Histopathology | |||||||||||||||||
Appearance | Itching | Fever | Tenderness | Other | Eosinophils | Serum IgE | ||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | |||||||||||||||
Skin disorders | Atopic dermatitis |
|
+ | + | Multiple |
|
– | + | – | – |
|
Nl to ↑ | ↑ |
|
| |||
Allergic contact dermatitis[1] |
|
– | + | Any | May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | + |
|
Nl to ↑ | Nl |
|
| ||
Irritant contact dermatitis[2] |
|
– | + | Any, more with occupational exposure | Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | – | + |
|
Nl | Nl |
|
| ||
Seborrheic dermatitis |
|
– | + | Any, onset during the infancy and peak during 3rd-4th decades | Multiple |
|
Scalp, face, trunk, postauricular, diaper area and axilla | + | + | – | – |
|
Nl | Nl |
|
| ||
Psoriasis |
|
+ | + | Any, 2 peaks of onset 30-39 years and 50-59 years | Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | _ | + |
|
Nl | Nl |
|
| ||
Lichen simplex [3]chronicus |
|
– | + | Any, peak at 30-50 years of age | Multiple | Lichenified and erythematous, pruritic exudative plaque, and excoriations | Scalp, head, neck, hands, arms, and genitals areas | – | + | – | – | Nl | Nl |
|
| |||
Ichthyosis vulgaris[4] |
|
+ | + | Usually in infancy | Multiple |
|
|
– | – | – | – |
|
Nl | Nl |
|
| ||
Nummular dermatitis (discoid eczema) | Unknown | – | + | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females | Multiple |
|
|
– | + | – | – |
|
Nl | Nl |
|
| ||
Netherton's syndrome[5] | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor | + | – | Affects neonates | Multiple |
|
|
+ | + | – | – |
|
Nl to ↑
(Eosinophilia) |
↑ |
|
| ||
Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Fever | Tenderness | Other | WBC | Serum IgE | Histopathology | Associated factors | ||
Infection | Molluscum contagiosum | Molluscum contagiosum virus inoculation through direct skin contact | – | + | Any, peak among children >5 years of age and young adults | Multiple |
|
|
– | + | – | – | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | Nl | Nl |
|
| |
Immunologic disorders | Dermatitis herpetiformis[6] | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | – | + | Any, mean age of disease onset is 2nd-4th decade | Multiple |
|
– | + | – | – |
|
Nl | Nl |
|
| ||
Immune deficiency | Wiskott-Aldrich syndrome[7] |
|
+ | – | Seen almost exclusively in males in infancy | Multiple |
|
Rash can involve lesions located at the same areas of classical atopic dermatitis:
extensor surfaces of extremities and cheeks or scalp |
– | + | – | – | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura,hematemesis, melena, epistaxis, hematuria or unusal bruising | Nl to ↑
(Eosinophilia) |
↑ |
|
| |
Hyper-IgE syndrome[8] |
|
+ | – | Rare, begin in infancy | Multiple |
|
|
+ | + | – | – |
|
Nl to ↑
(Eosinophilia) |
↑ |
|
| ||
Malignancy | Mycosis fungoides | Clonal expansion of CD4+ memory T cells (CD45RO+) | – | + | Mean age is 55- 60 years | Multiple |
|
|
– | + | – | – |
|
Nl | Nl |
|
| |
Category | Diseases | Etiology | Inherited | Acquired | Demography | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Fever | Tenderness | Other | WBC | Serum IgE | Histopathology | Associated factors |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
- ↑ Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
- ↑ Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
- ↑ Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
- ↑ Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
- ↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
- ↑ Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.